- 1 Title
- 2 The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and
- 3 receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan
- 4
- 5 Running Title
- 6 Diversity of antibody against SARS-CoV-2
- $\overline{7}$

```
8 Authors
```

9 Yudai Kaneko<sup>1,2</sup>, Akira Sugiyama<sup>1,3</sup>, Toshiya Tanaka<sup>1</sup>, Kazushige Fukui<sup>3</sup>, Akashi Taguchi<sup>1</sup>, Aya Nakayama<sup>3</sup>,

10 Kazumasa Koga<sup>4</sup>, Yoshiro Kishi<sup>2</sup>, Wang Daming<sup>5</sup>, Chungen Qian<sup>6</sup>, Fuzhen Xia<sup>7</sup>, Fan He<sup>7</sup>, Liang Zheng<sup>7</sup>, Yi Yu<sup>7</sup>,

- 11 Youichiro Wada<sup>1,3</sup>, Yoshiaki Wada<sup>4</sup>, Tatsuhiko Kodama<sup>1</sup>, Takeshi Kawamura<sup>1,3\*</sup>
- 12

## 13 Affiliations

- <sup>14</sup> Laboratory for Systems Biology and Medicine, Research Centre for Advanced Science and Technology (RCAST),
- 15 The University of Tokyo, Tokyo, Japan.
- 16 <sup>2</sup> Medical & Biological Laboratories Co., Ltd, Tokyo, Japan
- <sup>3</sup> Isotope Science Centre, The University of Tokyo, Tokyo, Japan.
- <sup>4</sup> Department of Neurology, Nissan Tamagawa Hospital, Tokyo, Japan.
- <sup>5</sup> Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences, Suzhou, China

- 20 <sup>6</sup> The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics –
- 21 Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical
- 22 Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Hubei,
- 23 China.
- <sup>24</sup> <sup>7</sup>Reagent R&D Centre, Shenzhen YHLO Biotech Co., Ltd, Guangdong, China.
- 25

```
26 * Corresponding author
```

- 27 Takeshi Kawamura, Isotope Science Centre, The University of Tokyo, 2-11-16 Yayoi, Bunkyo, Tokyo 113-0032,
- 28 Japan.
- 29 E-mail: kawamura@lsbm.org
- 30
- 31 Word count
- 32 Abstract: 239
- 33 Main text: 2487
- 34

#### 35 Abstract

- 36 Objectives:
- 37 To compare the temporal changes of IgM, IgG, and IgA antibodies against the SARS-CoV-2 nucleoprotein, S1
- 38 subunit, and receptor binding domain and neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with
- 39 COVID-19.
- 40 Methods:
- 41 A total of five patients in Nissan Tamagawa Hospital, Tokyo, Japan confirmed COVID-19 from August 8, 2020 to
- 42 August 14, 2020 were investigated. Serum samples were acquired multiple times from 0 to 76 days after symptom
- 43 onset. Using a fully automated CLIA analyzer, we measured the levels of IgG, IgA, and IgM against the
- 44 SARS-CoV-2 N, S1, and RBD and NAbs against SARS-CoV-2.
- 45 Results:
- 46 The levels of IgG antibodies against SARS-CoV-2 structural proteins increased over time in all cases but IgM and
- 47 IgA levels against SARS-CoV-2 showed different increasing trends among individuals in the early stage. In
- 48 particular, we observed IgA antibodies increasing before IgG and IgM in 3/5 cases. The NAb levels against
- 49 SARS-CoV-2 increased and kept above 10 AU/mL more than around 70 days after symptom onset in all cases.
- 50 Furthermore, in the early stage, NAb levels were more than cut off value in 4/5 COVID-19 patients some of whose
- antibodies against RBD didn't exceed 10 AU/mL.
- 52 Conclusions:
- 53 Our findings indicate that patients with COVID-19 should be examined for IgG, IgA and IgM antibodies against

- 54 SARS-CoV-2 structural proteins and NAbs against SARS-CoV-2 in addition to conventional antibody testing
- 55 methods for SARS-CoV-2 (IgG and IgM kits) to analyze the diversity of patients' immune mechanisms.
- 56 Key Words: SARS-CoV-2; COVID-19; antibody; neutralizing antibody; patient

57

## 58 Introduction

59	COVID-19 caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
60	caused a worldwide pandemic [1]. SARS-CoV-2 is a positive-sense single-stranded RNA virus of the
61	Coronaviridae family that is composed of an envelope (E), membrane (M), nucleoprotein (N), and spike (S) [2].
62	Coronaviruses entry and infect cells by binding the receptor binding domain (RBD) in the S1 subunit of their
63	trimeric spike proteins to angiotensin-converting enzyme 2 (ACE2) on cell surfaces [3] so a number of neutralizing
64	antibodies (NAbs) against SARS-CoV-2 were reported to target the RBD and block the binding between RBD and
65	ACE2 [4, 5]. As understanding the humoral immunity is important for developing drugs and vaccines for
66	COVID-19, measuring the levels of antibodies against SARS-CoV-2 structural proteins and NAbs against
67	SARS-CoV-2 over time will help identify key factors involved in the immune response. Measurements and
68	monitoring of antibodies (mainly IgG and IgM) against SARS-CoV-2 have already been performed, and some
69	study reported that antibodies are useful diagnostic tools for SARS-CoV-2 infections [6, 7]. However, the
70	longitudinal measurements of antibody isotypes against the SARS-CoV-2 structural proteins and NAbs against
71	SARS-CoV-2 in individuals have not been performed. Therefore, in the present study, we measured chronological
72	changes in the IgG, IgA, and IgM antibodies against the SARS-CoV-2 N, S1, and RBD and NAbs against
73	SARS-CoV-2.

74

75 Methods

76 Reagents and instruments

77	2019-nCoV IgM and IgG chemiluminescence immunoassay (CLIA) kits, detecting SARS-CoV-2 recombinant
78	antigen, were purchased from Shenzhen YHLO Biotech Co., Ltd (Shenzhen, China). Covid-2019 IgG Kit against N
79	antigen (recombinant N protein), Covid-2019 IgM Kit against N antigen (recombinant N protein), Covid-2019 IgA
80	Kit against N antigen (recombinant N protein), Covid-2019 IgG Kit against S1 antigen (recombinant S1 protein),
81	Covid-2019 IgM Kit against S1 antigen (recombinant S1 protein), Covid-2019 IgA Kit against S1 antigen
82	(recombinant S1 protein), Covid-2019 IgG Kit against RBD antigen (recombinant RBD protein), Covid-2019 IgM
83	Kit against RBD antigen (recombinant RBD protein), Covid-2019 IgA Kit against RBD antigen (recombinant RBD
84	protein) and iFlash-2019- nCoV NAb, a one-step competitive immunoassay, were obtained from Shenzhen YHLO
85	Biotech Co., Ltd (Shenzhen, China). A fully automatic CLIA analyzer (iFlash3000) was purchased from Shenzhen
86	YHLO Biotech Co., Ltd. We summarized all kits for immunoassays on Table 1.
87	
88	Patients
89	A total of five patients confirmed COVID-19 in Nissan Tamagawa Hospital from August 8, 2020 to August 14,
90	2020 were enrolled in this study. At least seven serum samples for each patient were collected from 0 to 76 days
91	after symptom onset. This study was performed at the University of Tokyo and Nissan Tamagawa Hospital
92	approved by their ethics committee (protocol number R2-05 and Tama2020-003).
93	
94	Serological test
95	Levels of IgG, IgA, and IgM against SARS-CoV-2 N, S1, and RBD and neutralizing antibody (NAb) against

- 96 SARS-CoV-2 were measured using a fully automatic CLIA analyzer (iFlash3000). The antibody concentrations
- 97 (AU/mL) were calculated based on the relative light units (RLU) obtained by the CLIA analyzer. The cut-off value
- 98 for indicating a positive test result as used by the manufacturer for all kits was 10 AU/mL.
- 99
- 100 **Results**
- 101 The subjects of this study were five men in their 20s to 50s with COVID-19. All infections were confirmed at
- 102 Nissan Tamagawa Hospital. Table 2 shows the symptoms exhibited by these patients. The most common symptom
- 103 was fever, with other symptoms including sore throat, cough, dysgeusia, and headache. Patient 2 and Patient 4
- 104 exhibited pneumonia. We didn't find correlation between symptom severity and Real Time PCR Ct values of
- 105 SARS-CoV-2.

106IgG and IgM levels against SARS-CoV-2 were measured using a fully automatic CLIA analyzer (iFlash3000) 107(Fig. 1). The IgM seroconversion time was slower than IgG. IgG levels against SARS-CoV-2 increased after 108 symptom onset, exceeding 10 AU/mL as early as 7 days (Fig. 1D) and as late as 17 days after symptom onset (Fig. 109 1E). In patients with pneumonia, it took a mean of 7 days for IgG antibody levels against SARS-CoV-2 to exceed 11010 AU/mL (Fig. 1B, D) while in other patients it took a mean of 16 days (Fig. 1A, C, E). In addition, IgG levels in 111 patients with pneumonia tended to increase over a long period while IgG levels in those with mild symptoms 112exhibited a decreasing trend starting from day 18. IgM antibody levels against SARS-CoV-2 in only two patients 113with pneumonia exceeded 10 AU/mL (Fig. 1B, D) while IgM levels against SARS-CoV-2 in other patients were 114lower than the cut-off value.

115	To evaluate antibodies against SARS-CoV-2 in greater detail, we measured levels of IgG, IgA, and IgM against
116	the N, S1, and RBD and NAbs against SARS-CoV-2 using a fully automatic CLIA analyzer (iFlash 3000) (Fig. 2).
117	IgG against N and S1 increased in the early stage, exceeding 10 AU/mL as early as day 7 (Fig. 2B) and as late as
118	day 17 (Fig. 2E) after symptom onset. In addition, it took 7 to 9 days for IgG against N and S1 to exceed 10 AU/mL
119	in patients with pneumonia (Fig. 2B, D) but it took 15 to 17 days in patients with mild symptoms (Fig. 2A, C, E).
120	In contrast, levels of IgM and IgA against N and S1 exhibited different increasing trends among patients in the
121	early stage. For example, in Patient 5, IgM and IgG levels were low but IgA levels were high on day 11.
122	Furthermore, in Patient 3 and Patient 5 who only exhibited one symptom, levels of IgA against N were already
123	slightly elevated on day 1 after symptom onset. In later stage, IgG levels remained flat followed by rise in all
124	samples while the levels of IgA fell gradually and below the cut-off value around day 70 in 4/5 patients. The
125	changes in levels of IgG, IgA, and IgM against RBD were similar to those of IgG, IgA, and IgM against S1 from
126	day 20 after COVID-19 symptom onset although the increasing trends of antibody levels against S1 weren't
127	different from those of the antibody levels against RBD in early stage.
128	NAbs against SARS-CoV-2 tended to increase, exceeding 10 AU/mL less than 15 days after symptom onset (Fig.
129	2). The peak levels of NAbs against SARS-CoV-2 in patients with pneumonia were much higher than NAbs levels
130	in those with mild symptoms. NAb levels stayed above 10 AU/mL more than around 70 days after symptom onset
131	while the levels of IgA and IgM against RBD dropped below 10 AU/mL around 70 days after symptom onset in 3/5
132	patients (Patient 2, Patient 3, and Patient 5). Furthermore, in the early stage, one or no antibody isotype against
133	RBD exceeded 10 AU/mL in 4/5 COVID-19 patients whose NAb levels were more than 10 AU/mL. For example,

134	in Patient 2 and Patient 4, only IgM levels against RBD were more than the cut-off value when the levels of NAbs
135	exceeded 10 AU/mL on day 7 and 8 after symptom onset, respectively. In Patient 3, the levels of any antibody
136	isotypes against RBD were less than 10AU/ml when NAb levels over the cut-off value from Day 9 to Day 11 after
137	symptom onset.
138	To analyze antibodies against SARS-CoV-2 in COVID-19 patients, we compared levels of IgG, IgA, and IgM
139	against the N, S1, and RBD and NAbs against SARS-CoV-2. We observed the higher correlation between the levels
140	of antibodies detected by using 2019-nCoV IgG and IgM CLIA kits and anti-N antibodies than anti-S and anti-RBD
141	antibodies (anti-N IgG: R^2=0.8804, anti-S1 IgG: R^2=0.7919, anti-RBD IgG: R^2=0.8196, anti-N IgM
142	R^2=0.9727, anti-S1 IgM: R^2=0.6832, anti-RBD IgM: R^2=0.6949) (Fig3A, B). Furthermore, there are very high
143	correlations between IgG, IgA, and IgM antibodies against S1 and RBD (IgG: R^2=0.9612, IgA: R^2=0.9794
144	IgM: R^2=0.9808) (Fig. 3C). The NAb levels were correlated most strongly with IgG levels of the antibody
145	isotypes (anti-N IgG: R^2=0.8447, anti-S1 IgG: R^2=0.9127 and anti-RBD IgG: R^2=0.9251, anti-N IgA
146	R^2=0.2226, anti-S1 IgA: R^2=0.2087, anti-RBD IgA: R^2=0.2202, anti-N IgM: R^2=0.3115, anti-S1 IgM
147	R^2=0.7947 and anti-RBD IgM: R^2=0.7657) (Fig. 4).
148	

## 149 **Discussion**

In this study, we examined the levels of IgG, IgA, and IgM antibodies against SARS-CoV-2 N, S1, and RBD and NAbs against SARS-CoV-2 in patients' sera with COVID-19 using a fully automated CLIA analyzer. Our results demonstrated the serological diversity of serum IgG, IgA, and IgM antibodies against the SARS-CoV-2 N,

153	S1 and RBD and NAbs against SARS-CoV-2 in patients with COVID-19 and the necessity of combinational
154	measurements of the antibody isotype levels against each structural protein of SARS-CoV-2 and NAb levels.
155	Using 2019-nCoV IgG kits and 2019-nCoV IgM kits, the chronological change of IgG antibody in patients with
156	COVID-19 found in this study is in line with other recent publications. Several reports showed that IgG levels were
157	higher in the later stages after symptom onset in severe cases than those in mild cases and that patients who die
158	from COVID-19 exhibit higher IgM levels [8,9]. Our results show that IgG antibody levels against SARS-CoV-2 in
159	the later stage and IgM antibody levels against SARS-CoV-2 could be useful for diagnosing the severity of the
160	disease. Our results showed that seroconversion time of IgM was slower than that of IgG in COVID-19 patients'
161	sera after symptom onset. A recent study also reported that IgM seroconversion was later than that of IgG in some
162	cases [10], not being consistent with the typical model that IgM seroconversion time is faster than IgG in the early
163	stage after viral infections. These data suggest that individuals who were not confirmed SARS-CoV-2 infection
164	may already have antibodies possessing cross-reactivity with SARS-CoV-2 in some cases, being infected by a
165	member of the coronavirus family.
166	The IgG and IgM levels were correlated strongly with the antibody levels against SARS-CoV-2 N proteins. In
167	particular, we observed the high correlation between the levels of antibodies measured by using 2019-nCoV IgG
168	and IgM CLIA kits and anti-N antibodies at low antibody levels. According to the manufacturer, 2019-nCoV IgG
169	and IgM CLIA kits detect antibodies against the SARS-CoV-2 recombinant antigen. We speculate that magnetic
170	microparticles are mainly coated with N antigens. In order to evaluate not only anti-N antibodies but also anti-S1
171	antibodies accurately, we need use the kit detecting the levels of antibodies against SARS-CoV-2 structural protein

172 as well as conventional testing kit (2019-nCoV IgG/IgM kit).

173	Using Covid-2019 IgG, IgA, and IgM kit against N, S1, and RBD antigen, levels of IgG against SARS-CoV-2
174	increased after symptom onset in all patients with COVID-19 but some cases exhibited different seroconversion
175	times such as IgA levels rising before IgG and IgM. A recent study reported that IgA levels in serum increased soon
176	after symptom onset with mild symptoms while that a case with the severity of symptoms showed a delayed but
177	very strong IgA response against SARS-CoV-2 [11]. Furthermore, measurement of serum IgA, in addition to
178	IgM and IgG, improved diagnostic accuracy for SARS-CoV-2 infections [12]. We also observed higher levels of
179	NAbs in patients with severe symptom than NAb levels in patients with mild symptom, using 2019-nCoV NAb kits.
180	The NAb levels were reported to increase after SARS-CoV-2 infection in most individuals [13] and be associated
181	with clinical disease severity [14, 15], confirming the results of our studies. IgA and NAb levels against
182	SARS-CoV-2 could be biomarker for COVID-19 severity.
183	There is the highest correlation between NAb and IgG levels against RBD of antibody isotypes in this study.
184	Furthermore, IgG levels against RBD are maintained in later stage, exhibiting similarly changes of NAb levels,
185	while the ratios of NAb levels to IgA and IgM levels against RBD continuously increased starting on day 18 after
186	COVID-19 symptom onset in all cases. Our data suggested that isotype switching to IgG could take place and
187	serum IgG mainly could have neutralizing activity against SARS-CoV-2 in the later stage, being consistent with a
188	recent study [16].

189 The NAb kit offer us some advantages by evaluating all antibodies having neutralization activity in the 190 COVID-19 patients. First, the NAb kit detects ACE2 competitively binding to RBD-coated particles with

191	antibodies against SARS-CoV-2 structural proteins while typical antibody kit against structural proteins detect each
192	isotype, not reflecting total NAb levels. In fact, we observed the levels of NAbs keeping above the cut off value
193	more than around 70 days after symptom onset in all COVID-19 patients some of whose antibody levels against
194	RBD lower than the cut-off value. Furthermore, some of antibody isotypes against RBD fall below 10AU/ml in
195	early stage while NAb levels exceed the cut-off value in 4/5 patients. Second, the levels of IgG, IgA, and IgM
196	against structural proteins weren't detected correctly, biased by different affinities and avidity of antibody isotypes.
197	The NAb kit could be as useful as IgG, IgA, and IgM kit against S1 and RBD for the accurate measurement of
198	antibodies having neutralizing activity in patients' sera with COVID-19.
199	However, there are some limitations in this study. First, the number of patients is the relatively small this study.
200	It is necessary for us to measure antibody levels in many COVID-19 patients' sera for a more accurate statistical
201	significance regarding the correlations between antibody isotypes and the severity of symptoms. Second, we didn't
202	detect neutralizing activity of each isotype against SARS-CoV-2 by the methods considering the bias of different
203	affinities of antibody isotypes as explained above. Furthermore, each antibody isotype affects the total NAb levels
204	at different times after infection because of different seroconversion. We observed IgA levels against S1 and RBD
205	declining followed by rise and below 10AU/mL around day 70 in all cases and a recent study also reported that IgA
206	levels in serum decreased notably 1 month after symptom onset, being more potent than IgG in neutralizing activity
207	for SARS-CoV-2 [17]. We need assess neutralizing activity of IgG, IgA, and IgM against SARS-CoV-2, using the
208	assay which can measure each isotype for understanding the role of these isotype against SARS-CoV-2. Third, we
209	detected NAbs against only RBD of SARS-CoV-2 in serum samples. Antibodies against S1 region except for RBD

210	of SARS-CoV-2 were reported to have neutralizing activity [18, 19]. We should detect NAbs by using S1-coated
211	particles, including RBD region for analyzing neutralization antibody. Last, we found the persistence of NAbs in
212	patients with COVID-19 around 70 days after symptom onset but we haven't measured the neutralization activity
213	of antibody for a longer time yet. Some longitudinal studies have reported that neutralization activity against
214	SARS-CoV-2 significantly declined as early as 6 weeks and that persisted as late as 5 months after symptom onset
215	[20, 21, 22]. Furthermore, the binding surface in SARS-CoV-2 RBD to ACE2 is reported to be less antigenic than
216	that of other S regions [23] so the antibody levels against RBD could go down earlier than antibody levels against
217	S1, which may affect chronological changes in NAb levels. Further longitudinal analysis of COVID-19 patients is
218	needed to understand immune memory after SARS-CoV-2 infection and vaccine.
219	
220	Conclusion
221	To further elucidate humoral immunity and other aspects of the immune mechanism of COVID-19, we must
222	combine measurements, such as levels of IgG, IgA, and IgM against SARS-CoV-2 N, S1, and RBD and NAbs
223	against SARS-CoV-2, in addition to using conventional testing methods (2019-nCoV IgG/IgM kit).
224	
225	Transparency declaration
226	The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or

publication of this article: 2019-nCoV IgM and IgG chemiluminescence immunoassay (CLIA) kits, Covid-2019

227

228 IgG/IgA/IgM Kit against N/S1/RBD antigen, and iFlash-2019- nCoV NAb were sponsored by Medical &

	229	<b>Biological Laboratories</b>	Co., Ltd.	and Shenzhen	YHLO Bi	otech Co., Ltd.
--	-----	--------------------------------	-----------	--------------	---------	-----------------

230

231	Fundin	g
-----	--------	---

- 232 This study was supported by grants from the Peace Winds Japan, Kowa Co., the Research Center for Advanced
- 233 Science and Technology, and Kodama laboratory in the University of Tokyo.
- 234

```
235 Acknowledgements
```

- 236 We would like to thank all the healthcare workers involved in treating COVID-19 patients at Nissan Tamagawa
- 237 Hospital.
- 238

## 239 Contribution

Yudai Kaneko performed data curation and analysis and drafted the manuscript. Kazushige Fukui, Akashi Taguchi, and Aya Nakayama performed data. Akira Sugiyama, Toshiya Tanaka, Youichiro Wada, Yoshiaki Wada, Tatsuhiko Kodama, and Takeshi Kawamura administrated experiments in the project and critically reviewed the manuscript. Kazumasa Koga collected samples. Yoshiro Kishi critically reviewed the manuscript. Chungen Qian, Fuzhen Xia, Fan He, Liang Zheng, and Yi Yu developed and provided the IgG, IgA, and IgM kits for SARS-CoV-2 N, S1, and RBD and the NAb kit against SARS-CoV-2. Wang Daming developed and provided the NAb kit against SARS-CoV-2.

## 247 **References**

- 248 [1] World Health Organization. (2020) Coronavirus disease (COVID-19) dashboard. Available from:
- 249 https://covid19.who.int/ Accessed 22nd August 2020
- 250 [2] Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85-164,
- 251 10.1016/B978-0-12-385885-6.00009-2.
- 252 [3] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry
- 253 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
- 254 181(2):271-280.e8, 10.1016/j.cell.2020.02.052. (Epub ahead of print)
- 255 [4] Shi R, Shan C, Duan X, Chen Z, Liu P, Song J et al. A human neutralizing antibody targets the receptor-binding
- 256 site of SARS-CoV-2. Nature. 2020;584(7819):120-124. doi: 10.1038/s41586-020-2381-y. (Epub ahead of print)
- 257 [5] Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L et al. Potent Neutralizing Antibodies against SARS-CoV-2
- 258 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell.
- 259 2020;182(1):73-84.e16. doi: 10.1016/j.cell.2020.05.025. (Epub ahead of print)
- 260 [6] Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M et al. Diagnostic accuracy of an automated
- 261 CLIA for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol. 2020; 92(9):1671-1675.
- 262 10.1002/jmv.25932. (Epub ahead of print)
- 263 [7] Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z et al. Diagnostic value and dynamic variance of serum antibody in
- coronavirus disease. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 2019;94:49-52. 10.1016/j.ijid.2020.03.065.
- 265 (Epub ahead of print)

- 266 [8] Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y et al. Immune phenotyping based on the
- 267 neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19.
- 268 Front Mol Biosci 2020;7:157, 10.3389/fmolb.2020.00157. (Epub ahead of print)
- 269 [9] Wang Z, Li H, Li J, Yang C, Guo X, Hu Z et al. Elevated serum IgM levels indicate poor outcome in patients
- 270 with coronavirus disease 2019 pneumonia: a retrospective case-control study. medRxiv. 2020;
- 271 10.1101/2020.03.22.20041285 (Epub ahead of print)
- [10] Long QX, Deng HJ, Chen J, Hu JL, Liu BZ, Liao P et al. Antibody responses to SARS-CoV-2 in COVID-19
- 273 patients: the perspective application of serological tests in clinical practice. medRxiv. 2020.
- $274 \qquad 10.1101/2020.03.18.20038018$
- [11] Dahlke C, Heidepriem J, Kobbe R, Santer R, Koch T, Fathi A et al. Distinct early IgA profile may determine
- severity of COVID-19 symptoms: an immunological case series. medRxiv. 2020. 10.1101/2020.04.14.20059733
- [12] Ma H, Zeng W, He H, Zhao D, Yang Y, Jiang D et al. COVID-19 diagnosis and study of serum SARS-CoV-2
- specific IgA, IgM and IgG by chemiluminescence immunoanalysis. medRxiv. 2020; 10.1101/2020.04.17.20064907
- 279 [13] Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS et al. Neutralizing antibody titres in
- 280 SARS-CoV-2 infections. Nat Commun. 2021;12(1):63. 10.1038/s41467-020-20247-4.
- [14] Jeewandara C, Jayathilaka D, Gomes L, Wijewickrama A, Narangoda E, Idampitiya D et al. SARS-CoV-2
- neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci Rep. 2021;11(1):2062.
- 283 10.1038/s41598-021-81629-2.
- [15] Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J et al. A longitudinal study of SARS-CoV-2-infected

- 285 patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol.
- 286 2021:1-10. 10.1038/s41423-020-00588-2. (Epub ahead of print)
- [16] Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH et al., Persistence of serum and saliva antibody
- responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. doi:
- 289 10.1126/sciimmunol.abe5511.
- [17] Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L et al. IgA dominates the early neutralizing antibody
- response to SARS-CoV-2. Sci Transl Med. 202113(577):eabd2223. 10.1126/scitranslmed.abd2223. (Epub ahead of
- 292 print)
- [18] Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y et al, Human-IgG-Neutralizing Monoclonal Antibodies Block
- the SARS-CoV-2 Infection. Cell Rep. 2020;32(3):107918. doi: 10.1016/j.celrep.2020.107918. (Epub ahead of
- 295 print)
- 296 [19] Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M et al. A neutralizing human antibody binds to the
- 297 N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650-655.
- 298 10.1126/science.abc6952. (Epub ahead of print)
- [20] Prévost J, Gasser R, Beaudoin-Bussières G, Richard J, Duerr R, Laumaea A et al. Cross-sectional evaluation of
- 300 humoral responses against SARS-CoV-2 spike. Cell Rep Med 2020;1(7):100126, 10.1016/j.xcrm.2020.100126.
- 301 (Epub ahead of print)
- 302 [21] Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M et al. Robust neutralizing antibodies to
- 303 SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227-1230. 10.1126/science.abd7728. (Epub

- ahead of print)
- 305 [22] Jeewandara C, Jayathilaka D, Gomes L, Wijewickrama A, Narangoda E, Idampitiya D et al. SARS-CoV-2
- neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci Rep. 2021;11(1):2062.
- 307 10.1038/s41598-021-81629-2.
- 308 [23] Hattori T, Koide A, Panchenko T, Romero LA, Teng KW, Tada T et al. The ACE2-binding interface of
- 309 SARS-CoV-2 Spike inherently deflects immune recognition. bioRxiv 2020; 10.1101/2020.11.03.365270. (Epub

310 ahead of print)

## 311 Figure legends

312 Table 1 Reagents for detecting antibody isotypes against SARS-CoV-2 struc	tructural proteins
---	--------------------

Antibody isotype	Antigen				
Antibody isotype	Nucleocapsid	Spike protein S1	Receptor bind	ing domain	
	iFlash-2019-nCoV IgG		– Covid-2019 IgG Kit		
IgG	Covid-2019 IgG Kit	Covid-2019 IgG Kit	against RBD antigen		
	against N antigen	against S1 antigen		-	
IgA	Covid-2019 IgA Kit	Covid-2019 IgA Kit	Covid-2019 IgA Kit	iFlash-2019-nCoV	
-8	against N antigen	against S1 antigen	against RBD antigen	NAb	
	iFlash-2019	C			
IgM	Covid-2019 IgM Kit	Covid-2019 IgM Kit	<ul> <li>Covid-2019 IgM Kit</li> <li>against RBD antigen</li> </ul>		
	against N antigen	against S1 antigen			

# Symptoms

No.	Age range	Sex	Ct value	Fever	Cough	Sore throat	Dysgeusia	Headache	Diarrhoea	Dyspnea
P1	20 - 29	Male	32.9	Yes	Yes	Yes	No	No	Yes	No
P2	40 - 49	Male	26.6	Yes	No	No	No	Yes	No	Yes
P3	30 - 39	Male	22.3	No	No	No	Yes	No	No	No
P4	50 - 59	Male	18.6	Yes	No	Yes	No	No	No	Yes
P5	30 - 39	Male	30.5	Yes	No	No	No	No	No	No

315






Figure 1. Timeline of IgG/IgM antibodies level against SARS-CoV-2 after symptom onset in patient P1(A), P2(B), P3(C), P4(D) and P5(E).





320 in patient P1(A), P2(B), P3(C), P4(D) and P5(E).

321



324 against RBD (C).





.

8

••